NCT02324543View on ClinicalTrials.gov

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

February 29, 2020

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
DRUG

Gemcitabine

IV on days 4 and 11 of a 21 day cycle

DRUG

Taxotere

IV on days 4 and 11 of a 21 day cycle

DRUG

Xeloda

Twice a day orally on days 1 through 14 of a 21 day cycle

DRUG

Cisplatin

IV on days 4 and 11 of a 21 day cycle

DRUG

Irinotecan

IV on days 4 and 11 of a 21 day cycle

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

Swim Across America

OTHER

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02324543 - Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter